Spero Therapeutics to Participate in the Chardan 10th Annual Healthcare Conference

CAMBRIDGE, Mass., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines in immunology and inflammation, today announced that Esther Rajavelu, Spero's President and Chief Executive Officer, will participate in a fireside chat at the Chardan 10th Annual Healthcare Conference to be held in New York City, on October 20th, 2026. Spero's leadership team will also be available for one-on-one meetings at the conference.

The webcast may also be accessed through Spero's website on the Events + Presentations page. A replay will be available for approximately 90 days following the conference. To request a meeting or for more details about the conference please contact your institutional representative at Chardan.

About Spero Therapeutics

Spero Therapeutics is a clinical-stage biopharmaceutical company focused on advancing next-generation medicines for patients with serious immune-mediated diseases. The company's lead program, SP001, is a third-generation, Fc-silent anti-CD40L monoclonal antibody being advanced first in IgG4-related disease, with potential for development in additional immunological & inflammatory diseases. For more information, visit www.sperotx.com.

Investor Relations Contact:
Shai Biran, PhD
Spero Therapeutics
[email protected]

Media Inquiries:
[email protected]

You May Also Be Interested In

• Pulse Seismic Inc. Reports Q3 2026 Financial Results and Declares Regular Quarterly Dividend
• Barry Gallant: The Questions to Ask Before Any Paving or Concrete Job Starts
• Amer Abdallah on the Warning Signs Fighters Miss Before Going International